New Haven-based Precipio announced this week that it had signed a deal with American Oncology Network (AON) of Fort Myers, Fla., to supply it with Precipio’s IV-Cell culture media.
AON, a network of cancer providers across 16 states, will use IV-Cell in its clinical cytogenetics laboratory, Precipio said in a news release. Terms of the transaction were not disclosed.
Used in the blood cancer diagnostic process, Precipio’s IV-Cell culturing media is a reagent intended to be used by cytogenetics laboratories for faster and more accurate diagnoses.
AON had previously tested and adopted Precipio’s HemeScreen, a proprietary mutation-screening technology.
Precipio CEO Ilan Danieli said, “We are dedicated to building our relationship with AON as we continue to innovate and commercialize our portfolio of high value, differentiated, diagnostic products.”
Based in New Haven’s Science Park, Precipio reported revenue gains in recent quarters and plans to grow, Danieli said last fall.
Contact Liese Klein at lklein@newhavenbiz.com.
